


WM-1119

Chemical Properties

CAS No. : 2055397-28-7
 Formula: C₁₈H₁₃F₂N₃O₃S
 Molecular Weight: 389.38
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	WM-1119 is a highly potent, selective KAT6A/B inhibitor
Targets(IC50)	Histone Acetyltransferase
In vitro	WM-1119 induces cell cycle exit and cellular senescence without causing DNA damage. It is 1,100-fold and 250-fold more active against KAT6A than against KAT5 or KAT7, respectively, demonstrating greater specificity for KAT6A than WM-8014. Testing WM-1119 at 1 μ M and 10 μ M against a pharmacological panel of 159 diverse biological targets reveals no affinity. Treatment of MEFs with WM-1119 results in cell cycle arrest in G1 and produces a senescence phenotype similar to WM-8014. Notably, the activity of WM-1119 in cell-based assays is an order of magnitude greater than WM-8014 and induces cell cycle arrest at 1 μ M. WM-8014 and WM-1119 both inhibit the proliferation of EMRK1184 lymphoma cells in vitro, with WM-1119 (IC ₅₀ =0.25 μ M) being ninefold more active than WM-8014 (IC ₅₀ =2.3 μ M), as expected based on reduced protein binding.
In vivo	Male C57BL/6-albino (B6(Cg)-Tyrc-2J/J) mice are injected intravenously with 100,000 EMRK1184 cells transfected with a luciferase-expression construct. Lymphoma growth is monitored. Three days after the lymphomacell transplant, all mice show luciferase activity, which indicate the expansion of lymphoma cells. Mice are then divided randomly into WM-1119-treatment with different concentrations (1, 2.5, 5, 10 μ M) and vehicle-control groups. Because WM-1119 is rapidly cleared after intraperitoneal injection, with the plasma concentration decreasing to below 1 μ M after 4-6 h cohorts of mice are injected every 8 h (three times per day, two cohorts of three mice per treatment group) or every 6 h (four times per day, two cohorts of three and six mice per treatment group). By day 14, the cohorts that are treated four times per day with WM-1119 have arrested tumour growth, with the exception of one mouse that does not respond. Spleen weights in the WM-1119-treatment group (treated four times per day) are substantially lower than spleen weights in the vehicle-treated group, and not significantly different from those of tumour-free eight-weekold mice. Treatment with WM-1119 three times per day leads to a significant reduction in tumour burden and spleen weight, but is not as effective as treatment four times per day. WM-1119 is well-tolerated; mice show no generalized ill effects and weight loss is not observed. WM-1119 treatment has no effect on haematocrit, erythrocytes or platelet numbers, but there is overall leukopenia. The proportion and overall number of tumour cells is substantially reduced by WM-1119 treatment (four times per day).

Animal Research	<p>Male C57BL/6-albino (B6(Cg)-Tyrc-2J/J) mice are injected intravenously with 100,000 EMRK1184 cells transfected with a luciferase-expression construct. Lymphoma growth is monitored. Three days after the lymphomacell transplant, all mice show luciferase activity, which indicate the expansion of lymphoma cells. Mice are then divided randomly into WM-1119-treatment with different concentrations (1, 2.5, 5, 10 μM) and vehicle-control groups. Because WM-1119 is rapidly cleared after intraperitoneal injection, with the plasma concentration decreasing to below 1 μM after 4-6 h cohorts of mice are injected every 8 h (three times per day, two cohorts of three mice per treatment group) or every 6 h (four times per day, two cohorts of three and six mice per treatment group). By day 14, the cohorts that are treated four times per day with WM-1119 have arrested tumour growth, with the exception of one mouse that does not respond. Spleen weights in the WM-1119-treatment group (treated four times per day) are substantially lower than spleen weights in the vehicle-treated group, and not significantly different from those of tumour-free eight-weekold mice. Treatment with WM-1119 three times per day leads to a significant reduction in tumour burden and spleen weight, but is not as effective as treatment four times per day. WM-1119 is well-tolerated; mice show no generalized ill effects and weight loss is not observed. WM-1119 treatment has no effect on haematocrit, erythrocytes or platelet numbers, but there is overall leukopenia. The proportion and overall number of tumour cells is substantially reduced by WM-1119 treatment (four times per day).</p>
-----------------	--

Solubility Information

Solubility	DMSO: 125 mg/mL (321.02 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	<p>10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.27 mM),Sonication is recommended.</p> <p><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i></p>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5682 mL	12.8409 mL	25.6819 mL
5 mM	0.5136 mL	2.5682 mL	5.1364 mL
10 mM	0.2568 mL	1.2841 mL	2.5682 mL
50 mM	0.0514 mL	0.2568 mL	0.5136 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Baell JB et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature. 2018 Aug;560(7717):253-257.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481